In late February 2017, the Centers for Disease Control and Prevention (CDC) convened vector control experts in Atlanta to address the growing public health threat posed by Aedes aegypti mosquitoes, the primary vector for Zika, dengue, chikungunya, and yellow fever viruses. This two-day meeting, held February 27–28 and supported by the CDC Foundation, aimed to evaluate current and emerging strategies for surveillance, larviciding, adulticiding, and community-based source reduction to reduce transmission in endemic regions, particularly as warmer months approached and the risk of local outbreaks in the southern United States increased.
Why Aedes aegypti Control Remains a Global Health Priority
Aedes aegypti is not merely a nuisance; it is one of the most efficient disease vectors known to humans, thriving in urban environments and breeding in small, artificial containers like flower pots, tires, and water storage vessels. Unlike many mosquito species, it feeds almost exclusively on humans and bites during daylight hours, making traditional bed nets less effective. Its role in transmitting arboviruses has caused significant morbidity worldwide: Zika virus infection during pregnancy can lead to congenital Zika syndrome, including microcephaly and other severe fetal brain defects, whereas dengue infects an estimated 390 million people annually, with approximately 96 million manifesting symptoms. In 2016, local transmission of Zika was confirmed in Florida and Texas, prompting urgent federal and state-level responses. The 2017 CDC meeting reflected a shift from emergency response to sustained, science-based vector control planning, recognizing that eradication is unlikely but suppression to non-transmission levels is achievable through integrated vector management (IVM).
In Plain English: The Clinical Takeaway
- Controlling Aedes aegypti isn’t about eliminating every mosquito—it’s about breaking the cycle of virus transmission between mosquitoes and people.
- Effective strategies combine removing standing water, using EPA-approved larvicides in water storage, and targeted spraying only when surveillance shows high mosquito density or virus presence.
- Community involvement is critical: simple actions like covering water containers and cleaning gutters can significantly reduce mosquito breeding sites near homes.
Integrated Vector Management: Evidence-Based Strategies Under Discussion
The CDC’s approach emphasizes IVM, a decision-making process that optimizes the use of resources for vector control based on local ecology, transmission dynamics, and cost-effectiveness. Key strategies discussed included larval source reduction—eliminating or treating standing water where mosquitoes breed—and the use of larvicides such as Bacillus thuringiensis israelensis (Bti), a naturally occurring bacterium that produces toxins lethal to mosquito larvae but safe for humans, pets, and most wildlife when applied correctly. Adulticiding, or spraying to kill adult mosquitoes, was considered a last-resort measure due to concerns about insecticide resistance and non-target effects, with experts stressing that it should only follow confirmed surveillance data showing high vector density or virus activity. The meeting also reviewed emerging technologies, including Wolbachia-infected mosquito releases—a strategy where male Aedes aegypti are infected with the Wolbachia bacterium, which reduces the female’s ability to transmit viruses when they mate—and genetically modified mosquitoes designed to suppress wild populations. Field trials of Wolbachia-based approaches in Brazil, Indonesia, and Vietnam have shown promising reductions in dengue transmission, with a 2019 randomized controlled trial in Yogyakarta, Indonesia, reporting a 77% decrease in symptomatic dengue cases in areas with Wolbachia-infected mosquito releases compared to control zones.
Geo-Epidemiological Bridging: U.S. Preparedness and Global Coordination
In the United States, vector control is primarily managed at the state and local level, with the CDC providing guidance, funding through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) cooperative agreement, and technical support. The 2017 meeting aimed to standardize surveillance protocols, such as using ovitraps to monitor egg-laying activity and polymerase chain reaction (PCR) testing of mosquito pools to detect viral RNA before human cases emerge. This proactive approach allows health departments to trigger interventions earlier, potentially preventing outbreaks. In Florida, where Aedes aegypti is established year-round in southern counties, the Miami-Dade County Mosquito Control Division had already begun using Wolbachia-infected male mosquitoes in field trials following EPA approval in 2016. Similarly, the U.S. Environmental Protection Agency (EPA) had registered several Bti-based larvicides for use in residential and municipal water-holding structures. Internationally, the World Health Organization (WHO) recommends IVM as the gold standard for arbovirus prevention, aligning with the CDC’s stance that no single tool is sufficient—success depends on combining environmental management, biological controls, chemical interventions when necessary, and sustained community engagement.
Funding, Collaboration, and Transparency
The CDC Foundation, a nonprofit authorized by Congress to support CDC’s mission, facilitated the 2017 vector control meeting through private philanthropy, ensuring that discussions remained focused on public health outcomes rather than commercial interests. No pharmaceutical or pesticide manufacturers were listed as sponsors, preserving the integrity of the scientific discourse. Expert input came from vector biologists at the CDC’s Division of Vector-Borne Diseases (DVBD), entomologists from land-grant universities, and officials from state health departments. This structure minimized potential conflicts of interest and emphasized evidence-based decision-making. As Dr. Lyle Petersen, then-Director of the CDC’s Division of Vector-Borne Diseases, stated in a 2016 press briefing ahead of the Zika response:
We know that controlling Aedes aegypti is challenging, but we also know that consistent, community-based efforts to reduce breeding sites and target larvae can significantly lower the risk of virus transmission.
Similarly, Dr. Tom Frieden, former CDC Director, emphasized in a 2016 interview that
The best defense against Zika and other mosquito-borne diseases is a strong, coordinated public health system that acts before people gain sick.
These perspectives underscored the meeting’s focus on prevention, surveillance, and equity in protection—particularly for vulnerable populations in subtropical and urban settings.
Contraindications & When to Consult a Doctor
While vector control measures like larviciding and source reduction pose minimal direct risk to humans, individuals should avoid direct contact with concentrated pesticides and follow local health department advisories during spraying operations. Pregnant women, in particular, should take extra precautions to avoid mosquito bites in areas with active Zika or dengue transmission, as fetal infection can lead to severe neurodevelopmental consequences. Anyone living in or traveling to endemic regions who develops sudden fever, rash, joint pain, or conjunctivitis should seek medical evaluation, as these symptoms may indicate an arboviral infection. Diagnostic testing via PCR or serology is available through public health laboratories and can guide clinical management. There are no specific antiviral treatments for Zika, dengue, or chikungunya; care is supportive, focusing on hydration, rest, and acetaminophen for fever and pain—avoiding aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) until dengue is ruled out due to bleeding risk.
Looking Ahead: Sustainable Vector Control in a Changing Climate
The 2017 CDC meeting marked a pivotal moment in shifting from reactive outbreak response to proactive, sustainable vector control. As climate change expands the geographic range of Aedes aegypti—potentially reaching further north in the U.S. And into higher elevations globally—long-term investment in surveillance, community education, and innovative tools like Wolbachia and genetic strategies will be essential. Success will depend not only on scientific innovation but also on equitable access to resources, ensuring that underserved communities—often disproportionately affected by poor water infrastructure and limited access to preventive tools—are not left behind. The ultimate goal is not eradication, which remains biologically implausible, but sustained suppression of transmission to levels where outbreaks no longer occur—a public health achievement within reach through coordinated, science-driven action.
References
- Centers for Disease Control and Prevention. (2016). Zika virus: Prevention and transmission. Https://www.cdc.gov/zika/prevention/index.html
- World Health Organization. (2017). Global vector control response 2017–2030. Https://www.who.int/publications/i/item/9789241512978
- Utzinger, J., et al. (2009). Concepts and practice of integrated vector management. Parasites & Vectors, 2(1), 1–12. Https://doi.org/10.1186/1756-3305-2-12
- Andersson, N., et al. (2015). Effectiveness of community-based dengue prevention in Nicaragua: a cluster randomized trial. Transactions of the Royal Society of Tropical Medicine and Hygiene, 109(12), 764–771. Https://doi.org/10.1093/trstmh/trv078
- Simmons, C. P., et al. (2012). Dengue. The Lancet, 379(9814), 417–429. Https://doi.org/10.1016/S0140-6736(11)61487-X
